TY  - JOUR
AU  - Gratacós, Jordi
AU  - Pontes, Caridad
AU  - Juanola, Xavier
AU  - Sanz, Jesús
AU  - Torres, Ferran
AU  - Avendaño, Cristina
AU  - Vallano, Antoni
AU  - Calvo, Gonzalo
AU  - de Miguel, Eugenio
AU  - Sanmartí, Raimon
AU  - REDES-TNF investigators
PY  - 2019
DO  - 10.1186/s13075-018-1772-z
UR  - https://hdl.handle.net/10668/25952
T2  - Arthritis research & therapy
AB  - The objective was to determine if dose reduction is non-inferior to full-dose TNFi to maintain low disease activity (LDA) in patients already in remission with TNFi, in axial spondyloarthritis. Randomized, parallel, non-inferiority, open-label...
LA  - en
KW  - Dose-tapering
KW  - Non-inferiority
KW  - Spondyloarthritis
KW  - TNF inhibitors
KW  - Adalimumab
KW  - Adult
KW  - Antibodies, Monoclonal
KW  - Dose-Response Relationship, Drug
KW  - Etanercept
KW  - Female
KW  - Humans
KW  - Infliximab
KW  - Male
KW  - Middle Aged
KW  - Prospective Studies
KW  - Spondylarthritis
KW  - Tumor Necrosis Factor Inhibitors
KW  - Tumor Necrosis Factor-alpha
TI  - Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis.
TY  - research article
VL  - 21
ER  -